✦ LIBER ✦

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

✍ Scribed by Hutson, T. E.; Escudier, B.; Esteban, E.; Bjarnason, G. A.; Lim, H. Y.; Pittman, K. B.; Senico, P.; Niethammer, A.; Lu, D. R.; Hariharan, S.; Motzer, R. J.

Book ID: 121482508
Publisher: American Society of Clinical Oncology
Year: 2014
Tongue: English
Weight: 258 KB
Volume: 32
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2013.50.3961

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

860 PHASE III RANDOMIZED TRIAL OF SUNITI

860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ O. Rixe; T.E. Hutson; P. Tomczak; M.D. Michaelson; R.M. Bukowski; S. Oudard; S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 328 KB

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB

Randomized Phase II Trial of First-Line

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

✍ Coplen, D.E. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 69 KB

Randomized Phase III Trial of Temsirolim

Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial

✍ Rini, B. I.; Bellmunt, J.; Clancy, J.; Wang, K.; Niethammer, A. G.; Hariharan, S 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 266 KB

Phase II Placebo-Controlled Randomized D

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

✍ Ornstein, D.K.; Finley, D.S. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 56 KB

Phase III Study of Sunitinib Malate (SU1

Phase III Study of Sunitinib Malate (SU11248) Versus Interferon-α as First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma

✍ Kesava Reddy; Ronald M. Bukowski 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB